investorscraft@gmail.com

Stock Analysis & ValuationAnbio Biotechnology Class A Ordinary Shares (NNNN)

Previous Close
$28.90
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)27.94-3
Intrinsic value (DCF)3.10-89
Graham-Dodd Method0.69-98
Graham Formula1.64-94

Company Information

Wilhelm Gutbrod Str 21B
Frankfurt am Main 60437
Germany
Phone: 49 16 0962 47281
Industry: Medical - Instruments & Supplies
Sector: Healthcare
CEO: Michael Lau
Full Time Employees: 27

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.

HomeMenuAccount